The management of tuberculosis (TB) involves a combination of medical treatment, public health strategies, and supportive care. The primary goal is to cure the patient, prevent transmission, and reduce the incidence of drug-resistant TB. This article outlines the standard treatment regimens, the management of drug-resistant TB, and the role of public health interventions.
The standard treatment for active TB involves a combination of antibiotics over a period of at least six months. The most commonly used first-line anti-TB drugs are:
Structure of IsoniazidIsoniazid (INH): A bactericidal drug that inhibits the synthesis of mycolic acids, essential components of the mycobacterial cell wall.
Structure of RifampicinRifampicin (RIF): A bactericidal antibiotic that inhibits RNA synthesis by binding to the beta subunit of DNA-dependent RNA polymerase.
Structure of EthambutolEthambutol (EMB): A bacteriostatic agent that inhibits the synthesis of the mycobacterial cell wall by blocking arabinosyl transferases.
Structure of PyrazinamidePyrazinamide (PZA): A prodrug that is converted to its active form in acidic environments, disrupting mycobacterial cell membrane metabolism and transport functions.
Structure of StreptomycinStreptomycin (SM): An aminoglycoside antibiotic that inhibits protein synthesis by binding to the 30S subunit of the bacterial ribosome.
The initial phase of treatment typically lasts two months and includes all four drugs (INH, RIF, PZA, and EMB). This is followed by a continuation phase of four months with INH and RIF.
Drug-resistant TB, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), poses significant challenges. MDR-TB is resistant to at least isoniazid and rifampicin, while XDR-TB is resistant to these drugs plus any fluoroquinolone and at least one of the second-line injectable drugs.
Treatment of drug-resistant TB requires the use of second-line drugs, which are less effective, more toxic, and more expensive. The treatment duration is also longer, often extending to 18-24 months. Newer drugs such as bedaquiline and delamanid have been introduced to improve outcomes in drug-resistant TB cases.
Supportive care for TB patients includes nutritional support, management of comorbidities such as HIV/AIDS, and psychological support to address the stigma associated with the disease.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer. Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
